| Literature DB >> 30515878 |
Frank Konietschke1, Tim Friede2, Markus Pauly3.
Abstract
Count data are common endpoints in clinical trials, for example magnetic resonance imaging lesion counts in multiple sclerosis. They often exhibit high levels of overdispersion, that is variances are larger than the means. Inference is regularly based on negative binomial regression along with maximum-likelihood estimators. Although this approach can account for heterogeneity it postulates a common overdispersion parameter across groups. Such parametric assumptions are usually difficult to verify, especially in small trials. Therefore, novel procedures that are based on asymptotic results for newly developed rate and variance estimators are proposed in a general framework. Moreover, in case of small samples the procedures are carried out using permutation techniques. Here, the usual assumption of exchangeability under the null hypothesis is not met due to varying follow-up times and unequal overdispersion parameters. This problem is solved by the use of studentized permutations leading to valid inference methods for situations with (i) varying follow-up times, (ii) different overdispersion parameters, and (iii) small sample sizes.Entities:
Keywords: permutation methods; resampling; studentized statistics
Mesh:
Year: 2018 PMID: 30515878 PMCID: PMC6587510 DOI: 10.1002/bimj.201800027
Source DB: PubMed Journal: Biom J ISSN: 0323-3847 Impact factor: 2.207
Simulated designs, where and ,
| Setting |
| Sizes | Overdisp. | Interpretation |
|---|---|---|---|---|
| 1 | 1.5 |
|
| Balanced/equal overdispersion |
| 2 | 1.5 |
|
| Unbalanced/equal overdispersion |
| 3 | 1.5 |
|
| Balanced/unequal overdispersion |
| 4 | 1.5 |
|
| Unbalanced/unequal overdispersion (positive pairing) |
| 5 | 1.5 |
|
| Unbalanced/unequal overdispersion (negative pairing) |
| 6 | 10 |
|
| Balanced/equal overdispersion |
| 7 | 10 |
|
| Unbalanced/equal overdispersion |
| 8 | 10 |
|
| Balanced/unequal overdispersion |
| 9 | 10 |
|
| Unbalanced/unequal overdispersion (positive pairing) |
| 10 | 10 |
|
| Unbalanced/unequal overdispersion (negative pairing) |
Here , , , , , and denote vectors of overdispersion parameters and means that every component of , that is each group size, is increased by m.
Figure 1Type‐I error level (α = 5%) simulation results (y‐axis) of the statistics in (18), permutation test in (19) and ML‐based statistics for different distributions, sample size increments (x‐axis), where denote the realizations from . The simulation settings are described in Table 1
Figure 2Empirical coverage probabilities of nominal 95% confidence intervals of the corresponding confidence intervals given in (16), permutation‐ based confidence intervals given in (20) and ML‐based LRT statistics for different distributions and rate increments (x‐axis) and unequal overdispersion parameters (), where denote the realizations from
Type‐I error level (α = 5%) simulation results of the statistics in (18) and the permutation test in (19) using χ2‐square and exponentially distributed data in different designs, where denote the realizations from
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| 7 | 7 | 0.0567 | 0.1168 | 0.0440 | 0.0937 |
| 7 | 15 | 0.0479 | 0.1063 | 0.0373 | 0.0884 |
| 12 | 12 | 0.0521 | 0.0862 | 0.0500 | 0.0807 |
| 12 | 20 | 0.0473 | 0.0825 | 0.0364 | 0.0644 |
| 17 | 17 | 0.0498 | 0.0757 | 0.0355 | 0.0565 |
| 17 | 25 | 0.0521 | 0.0769 | 0.0540 | 0.0822 |
| 27 | 27 | 0.0535 | 0.0694 | 0.0854 | 0.1058 |
| 27 | 35 | 0.0522 | 0.0684 | 0.0454 | 0.0618 |
| 32 | 32 | 0.0544 | 0.0698 | 0.0469 | 0.0575 |
| 32 | 40 | 0.0494 | 0.0634 | 0.0526 | 0.0623 |
Estimated rates and overdispersion parameters (Variance / Mean Ratio) for the two example studies
| Endpoint | Group | Estimated rate | Sample variance | Estimated overdispersion |
|---|---|---|---|---|
| Pediatric MS trial ( | ||||
| T2 lesions | Control | 11.875 | 13.268 | 1.117 |
| Active | 10.625 | 16.839 | 1.585 | |
| Relapses | Control | 4.5 | 6.571 | 1.460 |
| Active | 2.375 | 0.268 | 0.113 | |
| Acyclovir trial ( | ||||
| Relapses | Control | 3.133 | 6.602 | 2.107 |
| ACYC | 2.067 | 3.030 | 1.466 | |
| Acyclovir trial ( | ||||
| Relapses | Control | 3.205 | 6.602 | 2.060 |
| ACYC | 2.118 | 3.172 | 1.498 | |
Statistical analysis of the examples using : Approximate method, Effect (), Standard Error (SE), Test Statistic (= Effect / SE), and 95% confidence intervals
| Method | Effect | SE | Statistic |
| 95% CI |
|---|---|---|---|---|---|
| T2 lesions | |||||
| Normal | 0.111 | 0.174 | 0.638 | 0.524 | (−0.231; 0.453) |
| LRT | 0.111 | 0.162 | 0.686 | 0.493 | (−0.207; 0.429) |
| LRT.Pool | 0.111 | 0.161 | 0.691 | 0.489 | (−0.204; 0.427) |
| Perm | 0.111 | 0.174 | 0.638 | 0.545 | (−0.269; 0.510) |
| NB‐Reg | 0.111 | 0.161 | 0.691 | 0.489 | (−0.204; 0.428) |
| Pois‐Reg | 0.111 | 0.149 | 0.745 | 0.456 | (−0.181; 0.405) |
| Relapses | |||||
| Normal | 0.639 | 0.216 | 2.964 | 0.003 | (0.216; 1.062) |
| LRT | 0.639 | 0.302 | 2.116 | 0.034 | (0.047; 1.231) |
| LRT.Pool | 0.639 | 0.284 | 2.254 | 0.024 | (0.083; 1.195) |
| Perm | 0.639 | 0.216 | 2.964 | 0.026 | (0.116; 1.162) |
| NB‐Reg | 0.639 | 0.284 | 2.254 | 0.024 | (0.096; 1.215) |
| Pois‐Reg | 0.639 | 0.284 | 2.254 | 0.024 | (0.096; 1.215) |
| Acyclovir relapses | |||||
| Normal | 0.416 | 0.215 | 1.939 | 0.052 | (−0.004; 0.837) |
| LRT | 0.416 | 0.228 | 1.824 | 0.068 | (−0.031; 0.863) |
| LRT.Pool | 0.416 | 0.231 | 1.805 | 0.071 | (−0.036; 0.868) |
| Perm | 0.416 | 0.215 | 1.939 | 0.054 | (−0.007; 0.842) |
| NB‐Reg | 0.416 | 0.231 | 1.805 | 0.071 | (−0.035; 0.870) |
| Pois‐Reg | 0.416 | 0.164 | 2.544 | 0.011 | (0.098; 0.741) |
| Acyclovir relapses (Secondary analysis) | |||||
| Normal | 0.414 | 0.218 | 1.904 | 0.057 | (−0.012; 0.841) |
| LRT | 0.414 | 0.230 | 1.798 | 0.072 | (−0.037; 0.866) |
| LRT.Pool | 0.414 | 0.233 | 1.781 | 0.075 | (−0.076; 0.845) |
| Perm | 0.414 | 0.218 | 1.904 | 0.062 | (−0.022; 0.845) |
| NB‐Reg | 0.415 | 0.233 | 1.780 | 0.075 | (−0.040; 0.874) |
| Pois‐Reg | 0.422 | 0.165 | 2.553 | 0.011 | (0.101; 0.750) |